|
BOXBOROUGH, Mass.--(BUSINESS WIRE)--Oct. 14, 2004--
Cytyc Corporation
(Nasdaq: CYTC) today announced that the London Region of the National
Health Service (NHS) intends to convert all cervical screening to
the ThinPrep(R) Pap Test. The London Region is comprised of five
sectors, which process approximately 650,000 Pap tests annually.
In October 2003, the National Institute for Clinical Excellence
(NICE) issued guidance recommending liquid-based cytology for cervical
screening. This exclusive arrangement with the London Region represents
a potential use of approximately 3.3 million ThinPrep Pap Tests
over the five-year term of this contract.
"We are extremely pleased with this decision. The thorough
technical evaluation in the London Region was focused on the clinical
performance of this test, and we commend those involved in this
process," said Daniel J. Levangie, Cytyc's executive vice president.
"The London Region is one of the largest regions in the UK
and combined with the previously announced agreements in Scotland,
the South West Region, and the South East (East) Region represent
a total potential use of more than 1.75 million ThinPrep Pap Tests
annually."
Cytyc Corporation is a leading medical device company that designs,
develops, manufactures, and markets innovative and clinically effective
products primarily focused on women's health. Cytyc products cover
a range of women's health applications, including cervical cancer
screening, breast cancer risk assessment, and treatment of excessive
menstrual bleeding. The ThinPrep(R) System is the most widely used
method for cervical cancer screening in the United States. The ThinPrep
System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000
Processor, ThinPrep(R) Imaging System, and related reagents, filters,
and other supplies. The ThinPrep System also provides the platform
from which the Company has launched its expansion into breast cancer
risk assessment with the FirstCyte(R) Breast Test. Cytyc Surgical
Products, a wholly owned subsidiary of Cytyc Corporation, manufactures
and markets the NovaSure(R) Impedance Controlled Endometrial Ablation
System, or the NovaSure(R) System, an innovative endometrial ablation
device to treat menorrhagia, or excessive menstrual bleeding.
Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.
Cytyc, ThinPrep, FirstCyte, and NovaSure are registered trademarks
of Cytyc Corporation.
|